Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Non-engineered multiantigen-targeted T-cells in patients with lymphoma

Spyridoula Vasileiou • 8 Feb 2021
TCT 2021
Lymphoma

Spyridoula Vasileiou, PhD, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, discusses the findings of an investigation evaluating an autologous T-cell product that targets multiple tumor-associated antigens expressed by lymphomas with the intent of treated disease and preventing immune escape in patients with chemorefractory lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Spyridoula Vasileiou

4:05
Allogeneic, off-the-shelf, COVID-19-specific T-cells
Spyridoula Vasileiou • 8 Feb 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals